Association between emphysema and chronic obstructive pulmonary disease outcomes in the COPDGene and SPIROMICS cohorts: A post hoc analysis of two clinical trials

Mei Lan K. Han; Nabihah Tayob; Susan Murray; Prescott G. Woodruff; Jeffrey L. Curtis; Victor Kim; Gerard Criner; Craig J. Galban; Brian D. Ross; Eric A. Hoffman; David A. Lynch; Ella Kazerooni; Fernando J. Martinez

doi:10.1164/rccm.201801-0051LE

Association between emphysema and chronic obstructive pulmonary disease outcomes in the COPDGene and SPIROMICS cohorts: A post hoc analysis of two clinical trials

Mei Lan K. Han, Nabihah Tayob, Susan Murray, Prescott G. Woodruff, Jeffrey L. Curtis, Victor Kim, Gerard Criner, Craig J. Galban, Brian D. Ross, Eric A. Hoffman, David A. Lynch, Ella Kazerooni, Fernando J. Martinez

Biostatistics

Research output: Contribution to journal › Letter › peer-review

28 Scopus citations

Original language	English (US)
Pages (from-to)	265-267
Number of pages	3
Journal	American journal of respiratory and critical care medicine
Volume	198
Issue number	2
DOIs	https://doi.org/10.1164/rccm.201801-0051LE
State	Published - Jul 15 2018

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.1164/rccm.201801-0051LE

Cite this

Han, M. L. K., Tayob, N., Murray, S., Woodruff, P. G., Curtis, J. L., Kim, V., Criner, G., Galban, C. J., Ross, B. D., Hoffman, E. A., Lynch, D. A., Kazerooni, E., & Martinez, F. J. (2018). Association between emphysema and chronic obstructive pulmonary disease outcomes in the COPDGene and SPIROMICS cohorts: A post hoc analysis of two clinical trials. American journal of respiratory and critical care medicine, 198(2), 265-267. https://doi.org/10.1164/rccm.201801-0051LE

Association between emphysema and chronic obstructive pulmonary disease outcomes in the COPDGene and SPIROMICS cohorts: A post hoc analysis of two clinical trials. / Han, Mei Lan K.; Tayob, Nabihah; Murray, Susan et al.
In: American journal of respiratory and critical care medicine, Vol. 198, No. 2, 15.07.2018, p. 265-267.

Research output: Contribution to journal › Letter › peer-review

Han, MLK, Tayob, N, Murray, S, Woodruff, PG, Curtis, JL, Kim, V, Criner, G, Galban, CJ, Ross, BD, Hoffman, EA, Lynch, DA, Kazerooni, E & Martinez, FJ 2018, 'Association between emphysema and chronic obstructive pulmonary disease outcomes in the COPDGene and SPIROMICS cohorts: A post hoc analysis of two clinical trials', American journal of respiratory and critical care medicine, vol. 198, no. 2, pp. 265-267. https://doi.org/10.1164/rccm.201801-0051LE

@article{42125e614c774ef695fed167e8b964fc,

title = "Association between emphysema and chronic obstructive pulmonary disease outcomes in the COPDGene and SPIROMICS cohorts: A post hoc analysis of two clinical trials",

author = "Han, {Mei Lan K.} and Nabihah Tayob and Susan Murray and Woodruff, {Prescott G.} and Curtis, {Jeffrey L.} and Victor Kim and Gerard Criner and Galban, {Craig J.} and Ross, {Brian D.} and Hoffman, {Eric A.} and Lynch, {David A.} and Ella Kazerooni and Martinez, {Fernando J.}",

note = "Funding Information: COPDGene is supported by NHLBI grants R01 HL089897 and R01 HL089856. The COPDGene project is also supported by the COPD Foundation through contributions made to an industry advisory board consisting of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, and HHSN268200900020C), which were supplemented by contributions made through the Foundation for the NIH from AstraZeneca; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici SpA; Forest Research Institute, Inc.; GSK; Grifols Therapeutics, Inc.; Ikaria, Inc.; Nycomed GmbH; Takeda Pharmaceutical Co.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi. M.K.H., F.J.M., B.D.R., C.J.G., and G.C. are supported by NHLBI grant R01 HL122438. M.K.H. is also supported by NHLBI grant K24 HL138118. Funding Information: This study was funded by AI135108 from the National Institute of Allergy and Infectious Diseases and by HL132523 and HL095021 from the NHLBI.",

year = "2018",

month = jul,

day = "15",

doi = "10.1164/rccm.201801-0051LE",

language = "English (US)",

volume = "198",

pages = "265--267",

journal = "American journal of respiratory and critical care medicine",

issn = "1073-449X",

publisher = "American Thoracic Society",

number = "2",

}

TY - JOUR

T1 - Association between emphysema and chronic obstructive pulmonary disease outcomes in the COPDGene and SPIROMICS cohorts

T2 - A post hoc analysis of two clinical trials

AU - Han, Mei Lan K.

AU - Tayob, Nabihah

AU - Murray, Susan

AU - Woodruff, Prescott G.

AU - Curtis, Jeffrey L.

AU - Kim, Victor

AU - Criner, Gerard

AU - Galban, Craig J.

AU - Ross, Brian D.

AU - Hoffman, Eric A.

AU - Lynch, David A.

AU - Kazerooni, Ella

AU - Martinez, Fernando J.

N1 - Funding Information: COPDGene is supported by NHLBI grants R01 HL089897 and R01 HL089856. The COPDGene project is also supported by the COPD Foundation through contributions made to an industry advisory board consisting of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, and HHSN268200900020C), which were supplemented by contributions made through the Foundation for the NIH from AstraZeneca; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici SpA; Forest Research Institute, Inc.; GSK; Grifols Therapeutics, Inc.; Ikaria, Inc.; Nycomed GmbH; Takeda Pharmaceutical Co.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi. M.K.H., F.J.M., B.D.R., C.J.G., and G.C. are supported by NHLBI grant R01 HL122438. M.K.H. is also supported by NHLBI grant K24 HL138118. Funding Information: This study was funded by AI135108 from the National Institute of Allergy and Infectious Diseases and by HL132523 and HL095021 from the NHLBI.

PY - 2018/7/15

Y1 - 2018/7/15

UR - http://www.scopus.com/inward/record.url?scp=85050148142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050148142&partnerID=8YFLogxK

U2 - 10.1164/rccm.201801-0051LE

DO - 10.1164/rccm.201801-0051LE

M3 - Letter

C2 - 29485901

AN - SCOPUS:85050148142

SN - 1073-449X

VL - 198

SP - 265

EP - 267

JO - American journal of respiratory and critical care medicine

JF - American journal of respiratory and critical care medicine

IS - 2

ER -

Association between emphysema and chronic obstructive pulmonary disease outcomes in the COPDGene and SPIROMICS cohorts: A post hoc analysis of two clinical trials

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Cite this